Evidence map›Paper›PMID 39441901›Full record

ArticleBlood2024

Deuterated water labeling in ibrutinib-treated patients with CLL: leukemia cell kinetics correlate with IGHV, ZAP-70, and MRD.

Ekaterina Kim, Shih-Shih Chen, Mariela Sivina, Hyunsoo Hwang, Xuelin Huang, Alessandra Ferrajoli, Nitin Jain, William G Wierda, Dominik Wodarz, Nicholas Chiorazzi and 1 more

Registry-linked trialAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Blood, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT01752426 (A Pilot Study to Determine the Effects of the Bruton's Tyrosine Kinase), which is not on this map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT01752426 phase1 / phase2completednot on this map

A Pilot Study to Determine the Effects of the Bruton's Tyrosine Kinase (Btk) Inhibitor PCI-32765 on Leukemia Cell Kinetics and Trafficking, Using Heavy Water Labeling in Subjects With Chronic Lymphocytic Leukemia (CLL) and Small Lymphocytic Lymphoma (SLL)

TypeinterventionalSponsorM.D. Anderson Cancer CenterRan2012 to 2018Enrolled30ConditionsLeukemiaArmsHeavy Water (2H2O), PCI-32765
3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Ekaterina KimDepartment of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX.
Shih-Shih ChenKarches Center for Oncology Research, The Feinstein Institutes for Medical Research, Northwell Health, Manhasset, NY.
Mariela SivinaDepartment of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX.
Hyunsoo HwangDepartment of Biostatistics, The University of Texas MD Anderson Cancer Center, Houston, TX.
Xuelin HuangDepartment of Biostatistics, The University of Texas MD Anderson Cancer Center, Houston, TX.ORCID 0000-0003-1192-9336
Alessandra FerrajoliDepartment of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX.ORCID 0000-0001-9547-4193
Nitin JainDepartment of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX.ORCID 0000-0003-0114-8384
William G WierdaDepartment of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX.ORCID 0000-0002-7357-270X
Dominik WodarzDepartment of Mathematics and Department of Ecology and Evolutionary Biology, University of California, Irvine, Irvine, CA.ORCID 0000-0002-8017-3707
Nicholas ChiorazziKarches Center for Oncology Research, The Feinstein Institutes for Medical Research, Northwell Health, Manhasset, NY.ORCID 0000-0003-1023-6650
Jan A BurgerDepartment of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX.ORCID 0000-0002-6177-7572

Funding

Tumor Evolution and Metastasis ProgramP30CA016672 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI DIANE BODURKA · 1985 to 2026
$290.8M
NCI NIH HHS P30 CA016672
6 · The paper itself

Abstract

abstractDeuterated ("heavy") water labeling in patients with chronic lymphocytic leukemia (CLL) demonstrates that IGHV unmutated and ZAP-70+ patients have higher blood and tissue CLL death rates on ibrutinib therapy, resulting in lower measurable residual disease levels with long-term ibrutinib treatment. This trial was registered at www.clinicaltrials.gov as #NCT01752426.

Indexed as

AdenineLeukemia, Lymphocytic, Chronic, B-CellNeoplasm, ResidualPiperidinesPyrazolesPyrimidinesZAP-70 Protein-Tyrosine KinaseAgedDeuteriumFemaleHumansImmunoglobulin Heavy ChainsImmunoglobulin Variable RegionKineticsMaleMiddle AgedAdenineDeuteriumibrutinibImmunoglobulin Heavy ChainsImmunoglobulin Variable RegionPiperidinesPyrazolesPyrimidinesWaterZAP70 protein, humanZAP-70 Protein-Tyrosine Kinase

Identifiers

PMID39441901
PMCPMC11830972

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.